| scholarly article | Q13442814 |
| P50 | author | Alain Sarasin | Q88474798 |
| Haitao Chu | Q42578465 | ||
| Joseph G. Ibrahim | Q64690943 | ||
| P2093 | author name string | Philippe Dessen | |
| Cheng Fan | |||
| Nancy E Thomas | |||
| Yingchun Zhou | |||
| Janiel M Shields | |||
| Maria J Sambade | |||
| Craig Carson | |||
| William K Kaufmann | |||
| Eldon C Peters | |||
| Bernard Omolo | |||
| Dennis A Simpson | |||
| Patrick Tompkins | |||
| P2860 | cites work | Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells | Q73010028 |
| Evaluation of telomerase activity in cutaneous melanocytic proliferations | Q73028600 | ||
| p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: an analysis of medically managed patients | Q73483273 | ||
| Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function | Q73722591 | ||
| Oncogene activation in melanocytes links reactive oxygen to multinucleated phenotype and senescence | Q82021676 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| A large-scale RNAi screen in human cells identifies new components of the p53 pathway | Q24319883 | ||
| Ribosomal protein S3: A multi-functional protein that interacts with both p53 and MDM2 through its KH domain | Q24321357 | ||
| Cluster analysis and display of genome-wide expression patterns | Q24644463 | ||
| Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26 | Q24653892 | ||
| Telomerase expression is sufficient for chromosomal integrity in cells lacking p53 dependent G1 checkpoint function | Q24815268 | ||
| The ubiquitin ligase COP1 is a critical negative regulator of p53 | Q28258057 | ||
| Genomic instability--an evolving hallmark of cancer | Q28274009 | ||
| Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics | Q28298703 | ||
| A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response | Q28592069 | ||
| Gene Expression Profiling of Primary Cutaneous Melanoma and Clinical Outcome | Q29011337 | ||
| Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma | Q29614282 | ||
| A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia | Q29615437 | ||
| Participation of p53 protein in the cellular response to DNA damage | Q29618319 | ||
| BRAFE600-associated senescence-like cell cycle arrest of human naevi | Q29619550 | ||
| p21 in cancer: intricate networks and multiple activities | Q30436015 | ||
| Analysis of gene expression data using BRB-ArrayTools. | Q33448521 | ||
| The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence | Q33588743 | ||
| Covariance-regularized regression and classification for high-dimensional problems | Q33591022 | ||
| Development and validation of predictive indices for a continuous outcome using gene expression profiles. | Q33889725 | ||
| Posttranslational modification of p53: cooperative integrators of function | Q33899450 | ||
| Cancer stem cells versus phenotype-switching in melanoma | Q34132378 | ||
| p53 Research: the past thirty years and the next thirty years. | Q34313764 | ||
| Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. | Q34634256 | ||
| Use of human tissue to assess the oncogenic activity of melanoma-associated mutations | Q34716087 | ||
| Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. | Q35083250 | ||
| Introduction: The Changing Directions of p53 Research | Q35103185 | ||
| Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi | Q35571122 | ||
| Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi | Q35987307 | ||
| Ataxia telangiectasia-mutated dependent DNA damage checkpoint functions regulate gene expression in human fibroblasts. | Q36713937 | ||
| P21 and p27: roles in carcinogenesis and drug resistance | Q37184060 | ||
| The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes | Q37197419 | ||
| An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. | Q37360211 | ||
| Melanoma prognostic model using tissue microarrays and genetic algorithms | Q37474252 | ||
| Diagnosis and treatment of melanoma brain metastasis: a literature review | Q37531863 | ||
| Molecular cytogenetics of cutaneous melanocytic lesions - diagnostic, prognostic and therapeutic aspects. | Q37670318 | ||
| Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway. | Q37760417 | ||
| p53 and its mutants in tumor cell migration and invasion | Q37832072 | ||
| p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition | Q39459195 | ||
| p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation | Q39654655 | ||
| Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability | Q39689315 | ||
| Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53. | Q39723681 | ||
| Oncogene-induced senescence does not require the p16(INK4a) or p14ARF melanoma tumor suppressors. | Q39884649 | ||
| C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells | Q39954044 | ||
| Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. | Q40014237 | ||
| Modeling genomic diversity and tumor dependency in malignant melanoma | Q40017348 | ||
| Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen | Q40024562 | ||
| Methylation-acetylation interplay activates p53 in response to DNA damage | Q40103473 | ||
| Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression | Q40114129 | ||
| Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma | Q40169723 | ||
| Cell cycle control, DNA repair and initiation of carcinogenesis. | Q40848335 | ||
| Evidence for the expression of radiation-induced potentially lethal damage being a p53-dependent process | Q40860766 | ||
| Expression of a novel form of p21Cip1/Waf1 in UV-irradiated and transformed cells | Q41050569 | ||
| Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. | Q41859138 | ||
| Phosphorylation and degradation of MdmX is inhibited by Wip1 phosphatase in the DNA damage response | Q41967616 | ||
| Cellular senescence in naevi and immortalisation in melanoma: a role for p16? | Q42016240 | ||
| Human papilloma virus type16 E6 deregulates CHK1 and sensitizes human fibroblasts to environmental carcinogens independently of its effect on p53. | Q42425307 | ||
| Malignancy without immortality? Cellular immortalization as a possible late event in melanoma progression | Q42775021 | ||
| Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature | Q42804978 | ||
| Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. | Q42806564 | ||
| p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. | Q45993768 | ||
| The Wip1 phosphatase and Mdm2: cracking the "Wip" on p53 stability | Q46857521 | ||
| Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets | Q46868093 | ||
| BRAF alterations are associated with complex mutational profiles in malignant melanoma | Q47349130 | ||
| P21 and Bax expression in cutaneous malignant melanomas: correlation with histologic prognostic parameters. | Q50976839 | ||
| Expression of mutant p53 in melanoma | Q68032750 | ||
| Mutation and expression of the p53 gene in malignant melanoma cell lines | Q70768852 | ||
| Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi | Q72089343 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 514-526 | |
| P577 | publication date | 2012-06-01 | |
| P1433 | published in | Pigment Cell & Melanoma Research | Q762851 |
| P1476 | title | A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines | |
| P478 | volume | 25 |
| Q36823687 | A prognostic signature of G(2) checkpoint function in melanoma cell lines |
| Q36301027 | ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment |
| Q36306149 | Bayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancer |
| Q38120311 | DNA repair and cell cycle checkpoint defects as drivers and therapeutic targets in melanoma. |
| Q36556389 | Effective intra-S checkpoint responses to UVC in primary human melanocytes and melanoma cell lines |
| Q40058161 | Frequent MYC coamplification and DNA hypomethylation of multiple genes on 8q in 8p11-p12-amplified breast carcinomas |
| Q37234933 | Gene expression signatures but not cell cycle checkpoint functions distinguish AT carriers from normal individuals |
| Q35564248 | IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma |
| Q37530284 | Is activation of the intra-S checkpoint in human fibroblasts an important factor in protection against UV-induced mutagenesis? |
| Q30539324 | MERTK receptor tyrosine kinase is a therapeutic target in melanoma. |
| Q39162918 | Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair |
| Q34026182 | Mechanisms of chromosomal instability in melanoma |
| Q35818484 | Oncogenic BRAF(V600E) Induces Clastogenesis and UVB Hypersensitivity |
| Q41859401 | Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment. |
| Q54983880 | Roles of UVA radiation and DNA damage responses in melanoma pathogenesis. |
| Q33578398 | Synthetic lethality: emerging targets and opportunities in melanoma |
| Q34001762 | Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma. |
| Q30413784 | Vascular channels formed by subpopulations of PECAM1+ melanoma cells |
Search more.